Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
NKGN NKGen Biotech	$0.24	$0.29	$0.10 ▼ $1.36	$10.79M	1.26	1.42 million shs	117,770 shs
NLSP NLS Pharmaceutics	$2.20 -0.9%	$2.21	$1.30 ▼ $15.59	$7.99M	0.18	856,862 shs	152,678 shs
PCSA Heatwurx	$0.22 +5.4%	$0.25	$0.15 ▼ $3.10	$2.53M	1.3	5.37 million shs	3.33 million shs
RNAZ TransCode Therapeutics	$9.69 -2.5%	$7.88	$6.15 ▼ $776.16	$8.29M	1.4	105,003 shs	11,511 shs

Analysts Agree—These Gold Picks Outshine the Rest

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
NKGN NKGen Biotech	0.00%	-20.03%	-4.00%	+77.78%	-79.83%
NLSP NLS Pharmaceutics	0.00%	+5.71%	-7.88%	+53.10%	+1,098.70%
PCSA Heatwurx	0.00%	-5.84%	-33.46%	-3.18%	-86.93%
RNAZ TransCode Therapeutics	0.00%	+14.38%	+31.31%	+18.33%	-99.96%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
NKGN NKGen Biotech	0.3306 of 5 stars	0.0	3.0	0.0	0.0	0.0	2.5	0.0
NLSP NLS Pharmaceutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
PCSA Heatwurx	2.1024 of 5 stars	3.5	2.0	0.0	0.0	0.0	1.7	1.3
RNAZ TransCode Therapeutics	2.0017 of 5 stars	3.5	4.0	0.0	0.0	0.6	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
NKGN NKGen Biotech	0.00	N/A	N/A	N/A
NLSP NLS Pharmaceutics	0.00	N/A	N/A	N/A
PCSA Heatwurx	3.00	Buy	$2.00	790.47% Upside
RNAZ TransCode Therapeutics	3.00	Buy	$280.00	2,789.58% Upside

Current Analyst Ratings Breakdown

Latest PCSA, NKGN, RNAZ, and NLSP Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
6/30/2025	PCSA Heatwurx	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$6.00 ➝ $2.00

(Data available from 7/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
NKGN NKGen Biotech	N/A	N/A	N/A	N/A	($2.68) per share	N/A
NLSP NLS Pharmaceutics	N/A	N/A	N/A	N/A	($0.37) per share	N/A
PCSA Heatwurx	N/A	N/A	N/A	N/A	$0.46 per share	N/A
RNAZ TransCode Therapeutics	N/A	N/A	N/A	N/A	($54.96) per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
NKGN NKGen Biotech	-$82.94M	-$2.45	N/A	∞	N/A	N/A	N/A	-479.36%	N/A
NLSP NLS Pharmaceutics	-$1.98M	N/A	0.00	∞	N/A	N/A	N/A	N/A	8/15/2025 (Estimated)
PCSA Heatwurx	-$11.85M	-$3.08	0.00	N/A	N/A	N/A	-319.56%	-232.40%	8/12/2025 (Estimated)
RNAZ TransCode Therapeutics	-$16.75M	N/A	0.00	N/A	N/A	N/A	-578.88%	-222.61%	8/13/2025 (Estimated)

Latest PCSA, NKGN, RNAZ, and NLSP Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	PCSA Heatwurx	-$0.23	N/A	N/A	N/A	N/A	N/A
5/21/2025	Q4 2024	RNAZ TransCode Therapeutics	-$2.00	-$0.60	+$1.40	-$2.51	$0.30 million	N/A
5/8/2025	Q1 2025	PCSA Heatwurx	-$0.77	-$0.30	+$0.47	-$0.30	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
NKGN NKGen Biotech	N/A	N/A	N/A	N/A	N/A
NLSP NLS Pharmaceutics	N/A	N/A	N/A	N/A	N/A
PCSA Heatwurx	N/A	N/A	N/A	N/A	N/A
RNAZ TransCode Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
NKGN NKGen Biotech	N/A	0.02	0.02
NLSP NLS Pharmaceutics	N/A	2.69	2.69
PCSA Heatwurx	N/A	2.93	2.93
RNAZ TransCode Therapeutics	N/A	5.20	5.20

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
NKGN NKGen Biotech	76.17%
NLSP NLS Pharmaceutics	N/A
PCSA Heatwurx	91.93%
RNAZ TransCode Therapeutics	N/A

Insider Ownership

Company	Insider Ownership
NKGN NKGen Biotech	10.36%
NLSP NLS Pharmaceutics	16.40%
PCSA Heatwurx	9.60%
RNAZ TransCode Therapeutics	0.01%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
NKGN NKGen Biotech	N/A	44.95 million	40.29 million	Not Optionable
NLSP NLS Pharmaceutics	6	3.60 million	3.01 million	Not Optionable
PCSA Heatwurx	20	11.88 million	10.74 million	Not Optionable
RNAZ TransCode Therapeutics	9	830,000	834,000	Not Optionable

PCSA, NKGN, RNAZ, and NLSP Headlines

Recent News About These Companies

TransCode Therapeutics (NASDAQ:RNAZ) Stock Rating Upgraded by Wall Street Zen

July 21 at 2:17 AM | americanbankingnews.com

Transcode Therapeutics Inc News (RNAZ) - Investing.com

July 4, 2025 | investing.com

TransCode Therapeutics Appoints Dr. Phillip D. Zamore to Science Advisory Board

May 28, 2025 | prnewswire.com

TransCode Therapeutics Successfully Completes Initial Dosing of Patients in Cohort 4 of Phase 1a Clinical Trial; No Dose Limiting Toxicities Reported

May 8, 2025 | prnewswire.com

TransCode Therapeutics, Inc.: TransCode Therapeutics Announces Effective Date for 1-for-28 Reverse Stock Split

May 6, 2025 | finanznachrichten.de

TransCode Therapeutics Announces Effective Date for 1-for-28 Reverse Stock Split

May 5, 2025 | prnewswire.com

TransCode Therapeutics approves reverse stock split to meet Nasdaq rules

May 4, 2025 | investing.com

TransCode reports progress in metastatic cancer trial

May 3, 2025 | uk.investing.com

TransCode Therapeutics Announces 1-for-28 Reverse Stock Split

May 2, 2025 | prnewswire.com

IBN Coverage: TransCode Therapeutics (NASDAQ: RNAZ) Advances Phase 1a Trial of RNA Cancer Therapy TTX-MC138

May 2, 2025 | finance.yahoo.com

TransCode Therapeutics (NASDAQ: RNAZ) Advances Phase 1a Trial of RNA Cancer Therapy TTX-MC138

May 2, 2025 | financial-news.co.uk

TransCode Therapeutics Reports Further Progress on Phase 1a Clinical Trial with No Dose Limiting Toxicities Reported in Patients with Metastatic Cancer

May 1, 2025 | prnewswire.com

TransCode Therapeutics, Inc. Announces Adjournment of Special Meeting and Information for Adjourned Special Meeting

April 21, 2025 | prnewswire.com

All You Need to Know About TransCode Therapeutics (RNAZ) Rating Upgrade to Buy

April 18, 2025 | zacks.com

Transcode Therapeutics price target lowered to $10 from $20 at H.C. Wainwright

April 17, 2025 | markets.businessinsider.com

Transcode Therapeutics begins dosing in fourth cohort of Phase 1 cancer trial

March 28, 2025 | markets.businessinsider.com

TransCode Therapeutics, Inc.: TransCode Therapeutics Announces Initial Dosing in Fourth Cohort of Phase 1 Clinical Trial with TTX-MC138

March 28, 2025 | finanznachrichten.de

TransCode Therapeutics Announces Initial Dosing in Fourth Cohort of Phase 1 Clinical Trial with TTX-MC138

March 27, 2025 | prnewswire.com

TransCode Therapeutics, Inc. Announces Closing of Registered Direct Offering

March 25, 2025 | prnewswire.com

Transcode to sell 10.25M shares at 98c per share in registered direct offering

March 25, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PCSA, NKGN, RNAZ, and NLSP Company Descriptions

NKGen Biotech NYSE:NKGN

$0.24 0.00 (0.00%)

As of 11:44 AM Eastern

NKGen Biotech, Inc. operates as a clinical-stage biotechnology company that focuses on the development and commercialization of autologous, allogeneic, and CAR-NK natural killer cell therapies. It develops SNK01, an autologous NK cell therapy; and SNK02, an allogeneic NK cell therapy, which are in Phase 1 clinical trials. The company was founded in 2017 and is based in Santa Ana, California.

NLS Pharmaceutics NASDAQ:NLSP

$2.20 -0.02 (-0.90%)

Closing price 04:00 PM Eastern

Extended Trading

$2.22 +0.02 (+0.91%)

As of 07:47 PM Eastern

NLS Pharmaceutics AG, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience to treat excessive daytime sleepiness and cataplexy; and Nolazol for the treatment of ADHD. The company also developing NLS-4, a selective dopamine reuptake inhibitor to prevent rare sleep disorders; NLS-3, a repurposed reverse ester of methylphenidate for treatment of ADHD; NLS-8, a melatonin ML1A receptor agonist, improved scopolamine-induced amnesia; NLS-11, a norepinephrine and dopamine reuptake inhibitor and muscarinic M1, M2, M3 receptor antagonist; and NLS-12, a norepinephrine and dopamine reuptake inhibitor and muscarinic M4 receptor antagonist. NLS Pharmaceutics AG was incorporated in 2015 and is based in Zurich, Switzerland.

Heatwurx NASDAQ:PCSA

$0.22 +0.01 (+5.45%)

Closing price 04:00 PM Eastern

Extended Trading

$0.23 +0.00 (+0.62%)

As of 07:59 PM Eastern

Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops chemotherapy drugs to improve the safety and efficacy of cancer treatment. Its drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of killing the cancer cells. The company's pipeline includes three chemotherapy drugs comprising Gemcitabine, PCS3117 that has completed Phase 2a clinical trials to treat pancreatic, biliary tract, lung, ovarian, breast, and other cancers; Capecitabine, a combination of PCS6422 and capecitabine that has completed Phase 1b clinical trials to treat metastatic colorectal, gastrointestinal, breast, pancreatic, and other cancers; and Irinotecan, PCS11T that is in pre-clinical studies to treat lung, colorectal, gastrointestinal, pancreatic, and other cancers. It also develops non-oncology drugs consisting of PCS12852 for treatment of gastroparesis; and PCS499 to treat patients with ulcerative and non-ulcerative necrobiosis lipoidica. The company has license agreements with Elion Oncology, Inc.; Ocuphire Pharma, Inc.; Aposense, Ltd.; Yuhan Corporation; and CoNCERT Pharmaceuticals, Inc. Processa Pharmaceuticals, Inc. was founded in 2011 and is based in Hanover, Maryland.

TransCode Therapeutics NASDAQ:RNAZ

$9.69 -0.25 (-2.52%)

Closing price 04:00 PM Eastern

Extended Trading

$9.59 -0.10 (-1.08%)

As of 05:57 PM Eastern

TransCode Therapeutics, Inc., a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others. The company is also developing TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; and TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B. In addition, the company developing TTX-RIGA, an RNA- based agonist of the retinoic acid-inducible gene I targeting activation of innate immunity in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9-based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines that activate cytotoxic immune responses against tumor cells. TransCode Therapeutics, Inc. was incorporated in 2016 and is based in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time